Clovis Oncology Company Profile (NASDAQ:CLVS)

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CLVS
  • CUSIP: 18946410
  • Web:
  • Market Cap: $3.84 billion
  • Outstanding Shares: 48,879,000
Average Prices:
  • 50 Day Moving Avg: $73.35
  • 200 Day Moving Avg: $69.15
  • 52 Week Range: $25.50 - $99.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -31.93
  • P/E Growth: 0.12
Sales & Book Value:
  • Annual Revenue: $21.74 million
  • Price / Sales: 176.63
  • Book Value: $7.04 per share
  • Price / Book: 11.16
  • EBIDTA: ($242,160,000.00)
  • Return on Equity: -177.30%
  • Return on Assets: -47.13%
  • Debt-to-Equity Ratio: 0.82%
  • Current Ratio: 3.26%
  • Quick Ratio: 3.23%
  • Average Volume: 1.82 million shs.
  • Beta: 1.58
  • Short Ratio: 4.95

Frequently Asked Questions for Clovis Oncology (NASDAQ:CLVS)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology, Inc. (NASDAQ:CLVS) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($1.29) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by $0.02. The firm earned $14.62 million during the quarter, compared to analysts' expectations of $13.07 million. The firm's quarterly revenue was down 32.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.07) earnings per share. View Clovis Oncology's Earnings History.

When will Clovis Oncology make its next earnings announcement?

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Clovis Oncology.

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?

17 brokerages have issued twelve-month price objectives for Clovis Oncology's shares. Their forecasts range from $38.00 to $125.00. On average, they expect Clovis Oncology's share price to reach $85.79 in the next year. View Analyst Ratings for Clovis Oncology.

What are analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

  • 1. Cann analysts commented, "In a presentation on Saturday at the 2017 European Society for Medical Oncology (ESMO) Congress, Clovis Oncology released additional details from the results of the phase III ARIEL3 study of Rucraca. In addition to PFS results, Clovis presented response rate data from an exploratory analysis of investigator-assessed ORR for patients with measurable disease at baseline. These response rate data are consistent with the previously released PFS data." (9/11/2017)
  • 2. According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca in Dec 2016. Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ sales. Rubraca is also under review in the EU for a comparable indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Promising progression-free survival and safety results from the ARIEL3 maintenance study is expected to help expand Rubraca’s label. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Rubraca is also set to face intense competition from currently marketed PARP inhibitors. Loss estimates have widened lately ahead of the Q2 results. Clovis has a mixed earnings surprise record in the recent quarters." (7/13/2017)
  • 3. Goldman Sachs Group, Inc. (The) analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
  • 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)

Who are some of Clovis Oncology's key competitors?

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:

  • M. James E. Barrett Ph.D., Independent Chairman of the Board
  • Patrick J. Mahaffy, President, Chief Executive Officer, Director
  • Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
  • Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer
  • Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
  • C. Dale Hooks, Senior Vice President, Chief Commercial Officer
  • Brian G. Atwood, Independent Director
  • James C. Blair Ph.D., Independent Director
  • Keith T. Flaherty M.D., Independent Director
  • Ginger L. Graham, Independent Director

Who owns Clovis Oncology stock?

Clovis Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.11%), Palo Alto Investors LLC (6.81%), PointState Capital LP (4.08%), State Street Corp (3.98%), FMR LLC (3.88%) and Franklin Resources Inc. (3.73%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read, James C Blair and Lindsey Rolfe. View Institutional Ownership Trends for Clovis Oncology.

Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including GAM Holding AG, Palo Alto Investors LLC, Versant Venture Management LLC, C WorldWide Group Holding A S, FMR LLC, Westfield Capital Management Co. LP, PDT Partners LLC and Blue Jay Capital Management LLC. Company insiders that have sold Clovis Oncology stock in the last year include Gillian C Ivers-Read and James C Blair. View Insider Buying and Selling for Clovis Oncology.

Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?

Clovis Oncology's stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Franklin Resources Inc., Eagle Asset Management Inc., Farallon Capital Management LLC, Fred Alger Management Inc., Macquarie Group Ltd., Vanguard Group Inc. and Samlyn Capital LLC. View Insider Buying and Selling for Clovis Oncology.

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of Clovis Oncology stock can currently be purchased for approximately $78.56.

MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  589
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $85.79 (9.20% upside)

Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/18/2017Leerink SwannReiterated RatingBuy$107.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform$81.00LowView Rating Details
9/11/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldLowView Rating Details
9/11/2017CannReiterated RatingHoldLowView Rating Details
8/18/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$73.00HighView Rating Details
8/10/2017Morgan StanleyReiterated RatingOverweight$93.00MediumView Rating Details
8/3/2017Bank of America CorporationReiterated RatingBuyLowView Rating Details
7/18/2017Credit Suisse GroupSet Price TargetBuy$107.00LowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$125.00HighView Rating Details
6/22/2017SunTrust Banks, Inc.Reiterated RatingBuyLowView Rating Details
6/20/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$67.00 -> $90.00HighView Rating Details
6/20/2017Janney Montgomery ScottUpgradeNeutral -> BuyMediumView Rating Details
6/19/2017Stifel NicolausBoost Price TargetBuy$86.00 -> $125.00HighView Rating Details
6/19/2017Chardan CapitalUpgradeSell -> Neutral$36.00 -> $50.00HighView Rating Details
3/28/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00LowView Rating Details
12/21/2016WallachBeth CapitalBoost Price TargetHold$22.00 -> $49.00N/AView Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00N/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Clovis Oncology (NASDAQ:CLVS)
Earnings by Quarter for Clovis Oncology (NASDAQ:CLVS)
Earnings History by Quarter for Clovis Oncology (NASDAQ CLVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($1.18)N/AView Earnings Details
8/2/2017Q2 2017($1.27)($1.29)$13.07 million$14.62 millionViewListenView Earnings Details
5/3/2017Q1 2017($1.43)($1.33)$6.04 million$7.05 millionViewListenView Earnings Details
2/22/2017Q416($1.65)($1.83)$0.08 millionViewListenView Earnings Details
11/3/2016Q316($1.95)($1.70)ViewListenView Earnings Details
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.39)($2.23)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($2.11)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.78)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.41)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.03)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.93)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
2017 EPS Consensus Estimate: ($4.97)
2018 EPS Consensus Estimate: ($2.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.53)($1.53)($1.53)
Q2 20173($1.30)($1.18)($1.23)
Q3 20173($1.24)($1.10)($1.15)
Q4 20173($1.12)($1.03)($1.06)
Q1 20181($0.85)($0.85)($0.85)
Q2 20181($0.67)($0.67)($0.67)
Q3 20181($0.64)($0.64)($0.64)
Q4 20181($0.51)($0.51)($0.51)
(Data provided by Zacks Investment Research)


Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Clovis Oncology (NASDAQ:CLVS)
Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 99.03%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Gillian C Ivers-ReadInsiderSell3,000$69.50$208,500.00View SEC Filing  
8/15/2017Gillian C Ivers-ReadInsiderSell3,000$70.05$210,150.00View SEC Filing  
8/4/2017James C BlairDirectorSell18,450$78.61$1,450,354.50View SEC Filing  
7/17/2017Gillian C Ivers-ReadInsiderSell3,000$91.56$274,680.00View SEC Filing  
6/15/2017Gillian C Ivers-ReadInsiderSell3,000$61.82$185,460.00View SEC Filing  
5/15/2017Gillian C Ivers-ReadInsiderSell3,000$47.39$142,170.00View SEC Filing  
4/17/2017Gillian C Ivers-ReadInsiderSell3,000$56.02$168,060.00View SEC Filing  
3/15/2017Gillian C Ivers-ReadInsiderSell3,000$66.99$200,970.00View SEC Filing  
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Clovis Oncology (NASDAQ:CLVS)
Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
DateHeadline logoClovis Oncology, Inc. (CLVS) Receives Average Recommendation of "Buy" from Analysts - September 20 at 10:46 AM logoAnalyzing Clovis Oncology (CLVS) and CytomX Therapeutics (CTMX) - September 19 at 6:10 PM logoToday's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology - September 19 at 5:17 PM logoClovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher - September 19 at 5:17 PM logoClovis Oncology, Inc. (CLVS) Rating Reiterated by Leerink Swann - September 19 at 2:32 PM logoHealth Care Sector Update for 09/18/2017: CLVS,LLY,ITUS,AEMD - Nasdaq - September 19 at 3:28 AM logoInsider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of Stock - September 18 at 7:44 PM logoClovis Oncology Inc. (CLVS) Has Broken Out Of Today's Range - September 18 at 5:20 PM logoSo Much PARP Inhibitor Deal Hype, So Little Payoff - September 18 at 5:20 PM logoClovis Up 10% On Double Normal Volume - September 18 at 5:20 PM logoClovis Oncology Higher Off Unconfirmed Takeover Chatter - September 18 at 12:34 PM logoClovis Oncology, Inc. (CLVS) Now Covered by Royal Bank Of Canada - September 14 at 6:06 PM logoClovis Oncology (CLVS) ARIEL3 Study of Rucaparib Published in The Lancet - - September 13 at 11:32 PM logoClovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet - September 13 at 6:31 PM logo$20.46 Million in Sales Expected for Clovis Oncology, Inc. (CLVS) This Quarter - September 13 at 3:32 AM logoShould You Keep Your Portfolio Healthy with Biotech ETFs? - September 12 at 5:57 PM logoClovis Oncology Inc (CLVS): Is the Pullback a Buying Opportunity? - September 11 at 5:57 PM logoA Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It - September 11 at 5:57 PM logoClovis Oncology's (CLVS) Hold Rating Reaffirmed at Oppenheimer Holdings, Inc. - September 11 at 3:50 PM logoClovis Oncology, Inc. (CLVS) Stock Rating Reaffirmed by Cann - September 11 at 8:10 AM logoClovis Oncology (CLVS) Reports Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment ... - - September 8 at 5:42 PM logoClovis Oncology (CLVS) Reports Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment ... - - September 8 at 5:42 PM logoClovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers - September 8 at 5:42 PM logoClovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound? - Nasdaq - September 7 at 10:31 PM logoClovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of ... - Business Wire (press release) - September 7 at 10:31 PM logoClovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017 - September 7 at 10:31 PM logoClovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound? - September 7 at 5:27 PM logoWhy Clovis Oncology Fell 7.1% in August - September 7 at 5:27 PM logoClovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress - August 30 at 5:16 PM logoAfter Gilead's Acquisition Of KITE, Who Gets Gobbled Up Next? - August 30 at 5:16 PM logoClovis Oncology, Inc. (CLVS) Receives Average Rating of "Buy" from Analysts - August 26 at 10:42 AM logoHere's Why Clovis Stock Is Up Almost 60% So Far in 2017 - Nasdaq - August 23 at 5:54 PM logoHere's Why Clovis Stock Is Up Almost 60% So Far in 2017 - August 23 at 5:54 PM logoOvarian Cancer Market Still Up For Grabs - August 18 at 5:21 PM logoTesaro: Losing It's Edge? - August 18 at 5:21 PM logoClovis Oncology's (CLVS) Buy Rating Reiterated at J P Morgan Chase & Co - August 18 at 11:22 AM logoClovis Oncology, Inc. (CLVS) PT Lowered to $107.00 - August 18 at 8:12 AM logoClovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : August 17, 2017 - August 16 at 10:45 PM logoClovis Oncology, Inc. (CLVS) Now Covered by Analysts at Evercore ISI - August 16 at 6:58 PM logoClovis (CLVS) Focuses on Label Expansion, Rubraca Impresses - Nasdaq - August 16 at 4:02 AM logoClovis Oncology, Inc. (CLVS) Insider Sells $210,150.00 in Stock - August 15 at 7:38 PM logoClovis (CLVS) Focuses on Label Expansion, Rubraca Impresses - August 15 at 5:58 PM logoSee what the IHS Markit Score report has to say about Clovis Oncology Inc. - August 11 at 5:43 PM logoSee what the IHS Markit Score report has to say about Clovis Oncology Inc. - August 11 at 5:43 PM logoClovis Oncology Enters Oversold Territory (CLVS) - Nasdaq - August 9 at 10:32 PM logoA Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision - Benzinga - August 9 at 3:07 AM logoInsider Selling: Clovis Oncology, Inc. (CLVS) Director Sells 18,450 Shares of Stock - August 8 at 7:44 PM logoClovis Oncology, Inc. Expected to Post FY2018 Earnings of ($2.60) Per Share (CLVS) - August 7 at 9:30 AM logoZacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Post Quarterly Sales of $18.58 Million - August 7 at 7:54 AM logoQ3 2017 EPS Estimates for Clovis Oncology, Inc. Reduced by Oppenheimer Holdings (NASDAQ:CLVS) - August 7 at 7:09 AM



Clovis Oncology (CLVS) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff